Overview

Price chart · mood · technical indicators

BIOA

BioAge Labs, Incstock Healthcare

Drug Manufacturers - Specialty & Generic

$16.62320.76%Current Market Mood:Neutral

Market Mood

Price Range (1Y)

$3.67$24.00

Current: $16.62

Market Comparison

vs Healthcare Sector & Drug Manufacturers - Specialty & Generic Industry

BIOA

+320.76%

1Y Performance

Healthcare

Sector 1Y

Drug Manufacturers - Specialty & Generic

Industry 1Y

Fundamentals

Updated daily after market close

P/E ratio—

EPS (TTM)$-2.240.0% YoY

Profit margin0.0%HEALTHCARE

Market cap$745.4MSmall cap

Wall Street coverage

$53.33median target· current $18.31 (+191.3%)7 analysts

Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.

Valuation

Forward P/E: —
PEG ratio: —
P/B: 2.73
P/S (TTM): 82.87
EV/EBITDA: —

Profitability & growth

ROE (TTM): -27.1%
Operating margin: -923.0%
Revenue growth YoY: 0.0%
Dividend yield: —
Beta: —

Last earnings

Mar 19, 2026 · Estimate $-0.67 · Reported $-0.72

Analyst estimate. Actual results often differ.

Ratios are point-in-time. Historical metrics — no guarantees about what comes next.

News & Sentiment

50 articles · sorted by date

Page 1 of 3 · 50 total

Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.

About BioAge Labs, Inc

Company profile

BioAmber Inc., an industrial biotechnology company, produces and sells bio-succinic acid to various customers in the chemical market primarily in the United States and Canada. The company is headquartered in Montreal, Canada.

Classification

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Exchange: NASDAQ
Country: USA
Currency: USD

Company profile

HQ: 5885 HOLLIS STREET, EMERYVILLE, CA
Fiscal year end: December
Latest quarter: Dec 31, 2025

Market cap$745.4M

Shares outstanding$44.4M

52W high$24.00

52W low$3.67

Educational content · Not investment advice or recommendations

We're educators, not advisors. Your decisions are your own. Disclaimer

Overview

BIOA

Market Comparison

Fundamentals

Wall Street coverage

Valuation

Profitability & growth

News & Sentiment

BioAge to preview early data for heart and retinal disease drug

BioAge to Host R&D Day Focused on NLRP3 Inhibition on May 8, 2026

BlackRock (NYSE: BIOA) reports 2.24M shares of BioAge; 5.03% stake

BioAge Labs (NASDAQ:BIOA) Trading 8.6% Higher - Here's Why

Wall Street Zen Downgrades BioAge Labs (NASDAQ:BIOA) to Sell

BioAge Labs (BIOA) CFO exercises 3,542 options, now holds 36,575 shares

BIOA FINAL DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages BioAge Labs, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important March 10 Deadline in Securities Class Action - BIOA

BIOA SEC Filings - BioAge Labs Inc. 10-K, 10-Q, 8-K Forms

BioAge Labs (Nasdaq:BIOA) - Stock Analysis

BioAge Labs (NASDAQ:BIOA) Stock Price Down 6.1% - Time to Sell?

Jefferies reiterates BioAge Labs stock rating on dose data By Investing.com

[ARS] BioAge Labs, Inc. SEC Filing

BioAge says early data suggest ‘best-in-class’ potential for inflammation drug

BGE-102 60 mg once daily achieves equivalent hsCRP reduction as 120 mg, BioAge Labs, Inc. finds

An oral inflammation drug cut a heart-risk marker 85% in BioAge trial

BioAge Reports Positive Phase 1 Data for BGE-102, a Novel Oral NLRP3 Inhibitor, Demonstrating Potential Best-in-Class Reductions in hsCRP

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 10, 2025 in BioAge Labs, Inc. Lawsuit - BIOA

BioAge Labs Highlights BGE-102 Catalysts, DME Study Plans and $285M Cash at Needham Conference

BioAge Labs to Present at 25th Annual Needham Virtual Healthcare Conference

BioAge Labs to Present at 25th Annual Needham Virtual Healthcare Conference

About BioAge Labs, Inc

Classification

Company profile

BIOA

Market Comparison

BIOA Market Analysis

Overview

BIOA

Market Comparison

Fundamentals

Wall Street coverage

Valuation

Profitability & growth

News & Sentiment

BioAge to preview early data for heart and retinal disease drug

BioAge to Host R&D Day Focused on NLRP3 Inhibition on May 8, 2026

BlackRock (NYSE: BIOA) reports 2.24M shares of BioAge; 5.03% stake

BioAge Labs (NASDAQ:BIOA) Trading 8.6% Higher - Here's Why

Wall Street Zen Downgrades BioAge Labs (NASDAQ:BIOA) to Sell

BioAge Labs (BIOA) CFO exercises 3,542 options, now holds 36,575 shares

BIOA FINAL DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages BioAge Labs, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important March 10 Deadline in Securities Class Action - BIOA

BIOA SEC Filings - BioAge Labs Inc. 10-K, 10-Q, 8-K Forms

BioAge Labs (Nasdaq:BIOA) - Stock Analysis

BioAge Labs (NASDAQ:BIOA) Stock Price Down 6.1% - Time to Sell?

Jefferies reiterates BioAge Labs stock rating on dose data By Investing.com

[ARS] BioAge Labs, Inc. SEC Filing

BioAge says early data suggest ‘best-in-class’ potential for inflammation drug

BGE-102 60 mg once daily achieves equivalent hsCRP reduction as 120 mg, BioAge Labs, Inc. finds

An oral inflammation drug cut a heart-risk marker 85% in BioAge trial

BioAge Reports Positive Phase 1 Data for BGE-102, a Novel Oral NLRP3 Inhibitor, Demonstrating Potential Best-in-Class Reductions in hsCRP

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 10, 2025 in BioAge Labs, Inc. Lawsuit - BIOA

BioAge Labs Highlights BGE-102 Catalysts, DME Study Plans and $285M Cash at Needham Conference

BioAge Labs to Present at 25th Annual Needham Virtual Healthcare Conference

BioAge Labs to Present at 25th Annual Needham Virtual Healthcare Conference

About BioAge Labs, Inc

Classification

Company profile

BIOA

Market Comparison